Patents Assigned to AstraZeneca
  • CHEMICAL PROCESS
    Publication number: 20080188657
    Abstract: A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described.
    Type: Application
    Filed: November 30, 2007
    Publication date: August 7, 2008
    Applicant: AstraZeneca UK Limited
    Inventor: Steven Robert LENGER
  • New Compounds I
    Publication number: 20080188502
    Abstract: The present invention relates to a compound of formula (I): as a free base or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical formulations containing said compound and to the use of said compound in therapy. The present invention further relates to a process for the preparation of compound of formula (I) and to new intermediates used therein.
    Type: Application
    Filed: June 27, 2007
    Publication date: August 7, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeremy Burrows, Fernando Huerta, Fredrik Lake, Torben Pedersen, Didier Rotticci, Tobias Rein, Karin Staaf, Ulrika Yngve
  • Carbazole derivatives and their use as NPY5 receptor antagonists
    Patent number: 7408064
    Abstract: The use of a compound of formula (I) in the manufacture of a medicament for the treatment, in a warm-blooded animal, of disorders mediated by the neuropeptide Y5 receptor: wherein: R1, R2, R3 and X1-X6 are as defined within or a pharmaceutically acceptable salt, prodrug or solvate thereof, is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: August 5, 2008
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Michael Howard Block, Wayne Brailsford
  • Compounds
    Patent number: 7407968
    Abstract: Compounds of formula (I) wherein RF1, RF2, Z, R1, R2, Ar, X and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds were prepared. These compounds are useful in therapy, in particular in the management of pain.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: August 5, 2008
    Assignee: AstraZeneca AB
    Inventors: Daniel Pagé, Christopher Walpole, Hua Yang
  • Quinazoline compounds
    Patent number: 7407946
    Abstract: Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: August 5, 2008
    Assignee: AstraZeneca AB
    Inventor: Andrew Austen Mortlock
  • P2Xreceptor antagonists and their use
    Patent number: 7408065
    Abstract: The invention provides compounds of formula (IA), processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: August 5, 2008
    Assignee: AstraZeneca AB
    Inventors: Richard Evans, Christine Eyssade, Rhonan Ford, Barrie Martin, Toby Thompson, Paul Willis
  • L-alanine derivatives as a5beta1 antagonists
    Publication number: 20080182842
    Abstract: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.
    Type: Application
    Filed: January 29, 2008
    Publication date: July 31, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jean-Claude Arnould, Benedicte Delouvrie, Christine Marie Paul Lambert-Van Der Brempt
  • Process For the Preparation of Alkyl Phosphinic Acids
    Publication number: 20080183007
    Abstract: The present invention relates to a new process for the synthesis of alkyl phosphinic acids, and more particularly to a coupling reaction between an alkylhalide and a hypophosphorous acid derivative by a radical initiated reaction. The invention also relates to compounds obtainable by the method of the invention.
    Type: Application
    Filed: October 5, 2005
    Publication date: July 31, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Mats Thelin
  • Novel Compounds
    Publication number: 20080182874
    Abstract: The invention provides compounds of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, in which A, n, p, q, R1, R2, R3 and R4 are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.
    Type: Application
    Filed: November 28, 2005
    Publication date: July 31, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Richard Evans, Rhonan Ford, Toby Thompson, Paul Willis
  • N-(2-Hydroxyethyl)-N-Methyl-4-(Quinolin-8-yl(1-(Thiazol-4-ylmethyl)Piperidin-4-ylidene)Methyl)Benzamide
    Publication number: 20080182875
    Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.
    Type: Application
    Filed: October 19, 2007
    Publication date: July 31, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Khanh Bui, Cathy Dantzman, Glen Ernst, Valerie Hoesch, Thomas Hudzik, Megan Murphy King, Jie Liu, Jingbo Yan
  • Therapeutic morpholino-substituted compounds
    Patent number: 7405211
    Abstract: Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: July 29, 2008
    Assignee: AstraZeneca AB
    Inventors: Alan D. Robertson, Shaun Jackson, Vijaya Kenche, Cindy Yaip, Hishani Parbaharan, Phil Thompson
  • Methods for Identifying a Patient as a Candidate for Treatment with a Long Acting Beta Agonist and for Predicting a Patient's Response to Long Acting Beta2 Agonist Therapy by Analysing Polymorphisms in the Beta2-Adrenergic Receptor Gene
    Publication number: 20080176224
    Abstract: A method for identifying a patient as a candidate for treatment with a long acting beta agonist comprises isolating a biological sample from a patient and identifying the presence or absence of at least one haplotype C. The presence of at least one haplotype C in a patient sample indicates that the patient is a good candidate for treatment. For example, the patient may have a respiratory disease such as an obstructive airway disease.
    Type: Application
    Filed: September 12, 2005
    Publication date: July 24, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Helen Jean Ambrose, Mitchell Joel Goldman
  • New Compounds 617
    Publication number: 20080176862
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: December 19, 2007
    Publication date: July 24, 2008
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Stefan Berg, Jorg Holenz, Sofia Karlstrom, Jacob Kihlstrom, Johan Lindstrom, Laszlo Rakos
  • Salt III
    Publication number: 20080176902
    Abstract: The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide hemi-fumarate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy.
    Type: Application
    Filed: July 31, 2006
    Publication date: July 24, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Julien Giovannini, Bo-Goran Josefsson
  • Chemical Compounds
    Publication number: 20080176872
    Abstract: This invention relates to novel compounds having the formula (I); and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: February 15, 2006
    Publication date: July 24, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Michelle Lamb, Tao Wang, Dingwei Yu, Peter Mohr, Bin Wang
  • New Pyridine Analogues VII 543
    Publication number: 20080176827
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: January 11, 2008
    Publication date: July 24, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Thomas Antonsson, Peter Bach, Kay Brickmann, Ruth Bylund, Fabrizio Giordanetto, Johan Johansson, Fredrik Zetterberg
  • Novel Compounds with Analgesic Effect
    Publication number: 20080176903
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Application
    Filed: December 5, 2007
    Publication date: July 24, 2008
    Applicant: ASTRAZENECA CANADA INC.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Positive modulators of nicotinic receptor agonists
    Patent number: 7402604
    Abstract: Compounds according to formula I: wherein R1, W, R2, R3, X, R4 and R5 are as described in the specification, enantiomers thereof, pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: July 22, 2008
    Assignee: AstraZeneca AB
    Inventors: David Gurley, James Rosamond
  • Substituted quinazoline derivatives as inhibitors of aurora kinases
    Patent number: 7402585
    Abstract: The invention provides quinazoline derivatives of formula (I): in the preparation of a medicament for use in the inhibition of Aurora kinase and also novel quinazoline derivatives, processes for their preparation, pharamceutical compositions containing them and their use in therapy
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: July 22, 2008
    Assignee: AstraZeneca AB
    Inventors: Frederic Henri Jung, Georges Rene Pasquet
  • New Pyridine Analogues IX 519
    Publication number: 20080171732
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: January 11, 2008
    Publication date: July 17, 2008
    Applicant: AstraZeneca AB
    Inventors: Thomas Antonsson, Ruth Bylund, Johan Johansson, Peter Bach, David Brown, Fabrizio Giordanetto